IGF-1

Modality

Insulin-like growth factor-1 (IGF-1), formerly known as somatostatin C, is a single-chain peptide consisting of 70 amino acids with three disulfide bridges. IGF1 is the major mediator of prenatal and postnatal growth, which regulates normal growth during childhood also exerts potent anabolic effects in adults.

Recombinant IGF-1 is licensed for the treatment of growth retardation in children with severe primary IGF-I deficiency (SPIGFD).

IGF-1 for Therapeutic Use

Recombinant human IGF-1, rhIGF-1

Mecacermin, a recombinant human IGF-1 (rhIGF-1), has been approved by the U.S. FDA to treat pediatric patients with postnatal growth failure and severe primary IGF-1 deficiency or growth hormone (GH) deficiency. The active ingredient of Mecasermin consists of 70 amino acids (~7.6 kDa), which is identical to endogenous human IGF-1.

The rhIGF-1 protein is produced in a bacteria system Escherichia coli (E. coli).

Figure 1. Structure formula of recombinant human IGF-1

R3 IGF-1

R3 IGF-I is a more biologically active hIGF-1 analogue that contains the complete amino acid sequence of human IGF-I with Glu3 (E3) replaced by Arg3 (R3), and a 13 amino acid stretch peptide at the N-terminus.

hIGF-1 Fusion Protein

Several clinical trials have been conducted with hIGF-1 conjugated or fused proteins, like IGF1-IGFBP3 (SHP607) for the prevention of chronic lung disease in preterm infants; vitronectin-IGF1 (VF001-DP) for the cure of chronic venous leg ulcers; IGF1-annexin A5 (SCP -776) used to treat congestive heart failure and acute ischemic stroke; IGF-MTX conjugate for the treatment of myelodysplastic syndromes.

Yaohai Bio-Pharma Offers One-Stop CDMO Solution for IGF-1

Approved Recombinant IGF-1

Generic name	Brand Name/Altermative name	Expression System	Indications	Manufacturer	R&D Stage
Mecasermin	FK780, Somazon	E. coli	LeprechaunismLaron syndromeRabson-Mendenhall syndromeCongenital generalized lipodystrophy	Astellas Pharma, Fujisawa Pharmaceutical	Approval
IGF-1	Igef	Pending Update	Dwarfism	Biogen, Inc.、Pharmacia & Upjohn, Inc.	Approval
Mecasermin biosimilar	Mecasermin (Ipsen)、rhIGF-I、Increlex、IGF-1 (Ipsen)、Somatomedin-1 (Ipsen)、Insulin-like growth factor-1 (Ipsen)、MKN-031	E. coli	DwarfismLaron syndromeincomplete growthgrowth hormone deficiencyInsulin-like growth factor I deficiency	Ipsen SA	Approved
Mecasermin biosimilar	Myotrophin, CEP-120, KW-6151	Pending Update	Amyotrophic Lateral SclerosisLou Gehrig’s disease	Cephalo, MSD	Failed to be approved
Mecasermin Rinfabate Recombinant，IPLEX	Mecasermin Rinfabate, SomatoKine, Premiplex, IPLEX, HGT-ROP-001, SHP-607, TAK 607, IGF-I/IGFBP-3	E. coli	Bronchopulmonary dysplasiaintraventricular hemorrhageLung diseaseRetinopathy of prematurity	Insmed，Takeda Pharmaceutical, Shire Plc	Phase II
Vitronectin-IGF-1 fusion protein	VF-001-DP-LD, VF001, VF 001, VitroGro	Yeast	Lower limb ulcersEye diseasesDiabetic foot	Dominion Minerals Ltd.	Phase II
Scp-776	Annexin A5-serum albumin-IGF-1 fusion protein	Pending Update	ischemic stroke	Silver Creek	Phase II
IGF-methotrexate conjugate	IGF-MTX Conjugated drugs, 765IGFMTX, Single domain antibody-Fc	E. coli	myeloid leukemiaMyelodysplastic syndrome	IGF Oncology	Phase I&II
MHB018A	Single domain antibody-Fc	Pending Update	Graves' ophthalmopathy	Minghui Pharmaceutical (Hangzhou) Co., Ltd.	Phase I
Insulin-Like Growth Factor 1	Pending Update	Pending Update	Nasolabial folds, sunburn	Wright State Physicians, Inc.	Phase I
MOD-13012	CTP-IGF-1 fusion protein, sustained-release IGF-1	Pending Update	Insulin-like growth factor I deficiency	OPKO Biologics (formerly Prolor Biotech),	Phase I
KT-A832	AAV-IGF1 - Kriya Therapeutics, KT-A832	Pending Update	type 1 diabetes	Kriya Therapeutics, Inc.	Pre-clinical
Chondrokin	Antibody fusion protein, IGF1-C11	Pending Update	Osteoarthritis	Philogen SpA	Pre-clinical
AZP-3404	Peptide, 9-peptide, IGFPB2	Pending Update	Insulin resistanceobesity	Millendo Therapeutics SAS, Amolyt Pharma SAS	Pre-clinical

All Categories

IGF-1

Modality

IGF-1

IGF-1 for Therapeutic Use

Recombinant human IGF-1, rhIGF-1

R3 IGF-1

hIGF-1 Fusion Protein

Yaohai Bio-Pharma Offers One-Stop CDMO Solution for IGF-1

Approved Recombinant IGF-1

MICROBIAL CDMO

Quick Links

GET IN TOUCH

Get in touch